Atrys Health Targets Revenues of €220 Million in 2022

Atrys Health is looking to the continuous market as an incentive to continue growing. The Spanish company that provides prediction, prevention, diagnosis, and precision medical treatment services, which has recently jumped to the continuous market, is confident of reaching revenues of $239 million (€220 million) in 2022, which would double the figure of $131.4 million (€121 million) reached in 2021, while gross operating profit (Ebitda) would stand at fifty million euros, compared to $39.5 million (€36.4 million) last year, as Santiago de Torres, president of Atrys Health, explained to PlantaDoce.

The president of Atrys Health gave a positive assessment of the 2021 financial year, in which the company launched the takeover bid for Aspy, various acquisitions such as that of the Portuguese group Lenitudes or the Swiss Radioonkologie Amsler AG, and refinanced its debt with a loan of $141 million (€130 million) led by Caisse de dépôt et placement du Québec (Cdpq), in which ING and Deutsche Bank also participated.

This agreement with Cdpq allows Atrys Health to extend the maturity of its financing until the end of 2028 and to obtain a line of fifty million euros to undertake new acquisitions, “as long as the covenants are met,” emphasizes De Torres.

Read more about Atrys Health and find the latest financial news in the world with the Born2Invest mobile app.

Atrys Health will manage the nuclear medicine area of the future SJD Pediatric Cancer Center

For De Torres, 2022 will be a year marked by organic growth, inorganic growth, and new partnership agreements with other companies, hospitals, or key players in the healthcare sector. “We will incorporate more companies and we will not carry out any more takeover bids,” the president of Atrys Health specified.

The Spanish company has signed agreements with partners such as Sanitas, with the start-up of an advanced oncological radiotherapy center in Barcelona and another in Madrid, as well as with the Sant Joan de Déu Hospital in Barcelona, a center where Atrys Health will make its nuclear medicine arsenal available.

The company will manage the nuclear medicine area of the future SJD Pediatric Cancer Center, which aims to become one of the largest pediatric oncology centers in Europe and one of the most important in the world, and which is scheduled to open in the middle of this year. The nuclear medicine area of the SJD Pediatric Cancer Center under the management of Atrys Health will have different state-of-the-art equipment for the metabolic diagnosis of tumors, offering PET-CT and Spect-CT imaging techniques.

Outside Spain, the company will continue to strengthen its presence in Latin America with the installation of a new radiotherapy service in Chile, as a result of its agreement with Sanitas.

The Spanish company does not rule out entering other markets

For De Torres, Atrys Health must aim to be a global company. The group currently has more than 2,500 professionals working in seven different countries.

“We are interested in having international investors to carry out global investments; the leap into the continuous market is a leap for the future,” says De Torres, who adds that the company intends to make itself known to international investors in other places such as London, Paris or Frankfurt.

Atrys Health structures its prevention and precision activity around five business units: telemedicine, oncology, pathology, prevention, and big data. Through these, it carries out conventional and advanced radiotherapy treatments, performs diagnostic tests in its own network of laboratories, analyzes radiology, cardiology, ophthalmology, and dermatology tests telematically, and provides smart and big data and data management services to the healthcare sector.

__

(Featured image by DarkoStojanovic via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.